Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference6 articles.
1. deSouza IS, Allen R, Shrestha P. Reassessment of confidence in a network meta-analysis of antidysrhythmic drugs for atrial fibrillation cardioversion. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07318-y.
2. Tsiachris D, Doundoulakis I, Pagkalidou E, Kordalis A, Deftereos S, Gatzoulis KA, et al. Pharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network meta-analysis. Cardiovasc Drugs ther. 2021;35(2):293–308.
3. deSouza IS, Tadrous M, Sexton T, Benabbas R, Carmelli G, Sinert R. Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis. Europace Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2020;22(6):854–69.
4. deSouza IS, Tadrous M, Sexton T, Benabbas R, Carmelli G, Sinert R. Pharmacologic cardioversion of recent-onset atrial fibrillation and flutter in the emergency department: a systematic review and network meta-analysis. Ann Emerg Med. 2020;76(1):14–30.
5. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.